Reported Earnings • Jun 30
First half 2025 earnings released: EPS: UK£0 (vs UK£0.002 loss in 1H 2024) First half 2025 results: EPS: UK£0 (improved from UK£0.002 loss in 1H 2024). Revenue: UK£1.47m (down 41% from 1H 2024). Net loss: UK£1.32m (loss narrowed 21% from 1H 2024). Duyuru • May 14
Versarien plc has completed a Follow-on Equity Offering in the amount of £0.425 million. Versarien plc has completed a Follow-on Equity Offering in the amount of £0.425 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,545,454,545
Price\Range: £0.000275
Transaction Features: Subsequent Direct Listing Reported Earnings • Mar 27
Full year 2024 earnings released: UK£0.003 loss per share (vs UK£0.055 loss in FY 2023) Full year 2024 results: UK£0.003 loss per share (improved from UK£0.055 loss in FY 2023). Revenue: UK£2.42m (down 56% from FY 2023). Net loss: UK£3.99m (loss narrowed 71% from FY 2023). Duyuru • Mar 27
Versarien plc, Annual General Meeting, Apr 28, 2025 Versarien plc, Annual General Meeting, Apr 28, 2025. Location: the offices of fieldfisher llp, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom Duyuru • Jan 29
Versarien plc has completed a Follow-on Equity Offering in the amount of £0.246038 million. Versarien plc has completed a Follow-on Equity Offering in the amount of £0.246038 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 745,569,784
Price\Range: £0.00033
Transaction Features: Subsequent Direct Listing New Risk • Dec 23
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Market cap is less than US$10m (UK£1.15m market cap, or US$1.45m). Minor Risk Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Duyuru • Dec 10
Versarien plc Announces the Launch of New Biosensors Versarien Plc announced the launch of a new biosensor chip utilising novel graphene barristor sensor platform technology. These graphene barristor devices, developed in South Korea by A Barristor Company ("ABC"), will utilise chemical vapour deposition ("CVD") grown graphene, that is produced under a Versarien licence. Versarien has signed a distribution agreement with ABC to distribute the products in the UK and Europe. A barristor (triode device) is a new type of graphene-based transistor with a Schottky barrier between graphene and silicon. The current modulation is amplified more than 10,000 times compared to graphene field-effect transistors ("GFET") enabling the barristor transistors to overcome many GFET limitations. In these new products, the graphene surface is terminated with either pyrenebutanoic acid succinimidyl ester ("PBASE") or a customer preferred linker. PBASE is one of the most frequently used linkers for the surface modification of field-effect transistor (FET) biosensors based on carbon nanotubes and graphene. The products can be supplied as individual chips or on a wafer scale. It is expected that the CVD graphene used in the products will be supplied by MCK Tech Co. Ltd. ("MCK Tech") in South Korea, which is an existing Licensing partner of Versarien, and it will also undertake some of the device fabrication. The range of sensor products to be distributed by Versarien may be expanded at a later date based on ABC's product developments, such as in infrared detection, gas/chemical detection, temperature detection or multiple sensor on a chip technology. Duyuru • Sep 30
Harper Bennett Limited completed a binding agreement to acquire AAC Cyroma Limited from Versarien plc (AIM:VRS) for £0.55 million. Harper Bennett Limited completed a binding agreement to acquire AAC Cyroma Limited from Versarien plc (AIM:VRS) for £0.55 million on September 30, 2024. The consideration of £0.55 million is payable in cash, in 16 equal quarterly instalments of £0.0034 million, commencing three months from completion. Versarien will retain a charge over the assets of AAC Cyroma and Harper Bennett Limited to cover any outstanding consideration payable. In the financial year ended 30 September 2023 AAC Cyroma incurred a loss of £0.146 million and had net assets at 30 September 2023 of £0.411 million. The disposal of AAC Cyroma is in line with the Company's strategy to focus on its core graphene technology and divesting of its mature businesses. The proceeds of the disposal will be used for the Company's general corporate and working capital purposes. Matthew Johnson, Adam Cowl of SP Angel Corporate Finance LLP acted as financial advisor for Versarien plc. Duyuru • Jul 25
Versarien plc has completed a Follow-on Equity Offering in the amount of £0.55 million. Versarien plc has completed a Follow-on Equity Offering in the amount of £0.55 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 846,153,845
Price\Range: £0.00065
Transaction Features: Subsequent Direct Listing New Risk • Jun 07
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -UK£1.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (460% increase in shares outstanding). Market cap is less than US$10m (UK£1.21m market cap, or US$1.54m). Duyuru • Mar 29
Versarien plc, Annual General Meeting, Apr 30, 2024 Versarien plc, Annual General Meeting, Apr 30, 2024, at 09:30 Coordinated Universal Time. Location: Riverbank House, 2 Swan Lane London United Kingdom Reported Earnings • Mar 28
Full year 2023 earnings released: UK£0.055 loss per share (vs UK£0.027 loss in FY 2022) Full year 2023 results: UK£0.055 loss per share (further deteriorated from UK£0.027 loss in FY 2022). Revenue: UK£5.45m (down 26% from FY 2022). Net loss: UK£13.5m (loss widened 156% from FY 2022). Duyuru • Mar 21
Versarien plc has completed a Follow-on Equity Offering in the amount of £0.615 million. Versarien plc has completed a Follow-on Equity Offering in the amount of £0.615 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 492,000,000
Price\Range: £0.00125
Transaction Features: Subsequent Direct Listing Duyuru • Jan 19
Versarien plc has completed a Follow-on Equity Offering in the amount of £0.4 million. Versarien plc has completed a Follow-on Equity Offering in the amount of £0.4 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 500,000,000
Price\Range: £0.0008
Transaction Features: Subsequent Direct Listing New Risk • Dec 26
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (156% increase in shares outstanding). Market cap is less than US$10m (UK£1.10m market cap, or US$1.40m). Minor Risk Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Duyuru • Nov 09
Versarien plc has completed a Follow-on Equity Offering in the amount of £0.454822 million. Versarien plc has completed a Follow-on Equity Offering in the amount of £0.454822 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 165,389,817
Price\Range: £0.00275
Transaction Features: Subsequent Direct Listing New Risk • Jul 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 70% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£4.9m free cash flow). Share price has been highly volatile over the past 3 months (40% average weekly change). Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (70% increase in shares outstanding). Market cap is less than US$10m (UK£4.40m market cap, or US$5.76m). Reported Earnings • Jun 11
First half 2023 earnings released: UK£0.015 loss per share (vs UK£0.011 loss in 1H 2022) First half 2023 results: UK£0.015 loss per share (further deteriorated from UK£0.011 loss in 1H 2022). Revenue: UK£2.62m (down 33% from 1H 2022). Net loss: UK£3.20m (loss widened 55% from 1H 2022). Duyuru • May 19
Versarien plc Provides an Update on the Trials of Versarien's Water-Based Graphene Admixture, CementeneTM in Precast Concrete Mixs That Have Been Carried Out by Banagher Precast Concrete Limited Versarien plc provided an update on the trials of Versarien's water-based graphene admixture, CementeneTM in precast concrete mixes that have been carried out by Banagher Precast Concrete Limited ("Banagher"), a precast concrete manufacturer and supplier of precast concrete products to the civil engineering and construction industries throughout the UK and Ireland. The Company reported that preliminary results from the work undertaken by Banagher have demonstrated that 20% of ordinary Portland cement ("OPC") can be removed from Banagher's typical precast concrete mix when CementeneTM is added, whilst maintaining the compression strength of the concrete. These initial results demonstrate the significant potential to reduce CO2 emissions without impacting the performance of the concrete. The production of 1 kg of CementeneTM is estimated to generate approximately 1.44 kg of CO2 emissions and approximately 5 kg of Cementene TM is used per cubic metre of concrete. The production of 1 km of OPC emits approximately 0.8 kg of CO2 and c.500 kg of OPC is used per cubic metre of Banagher's precast concrete. Therefore, the removal of 20% of OPC in the precast concrete mix (approximately 100 kg) equates to a net saving of approximately 72.8 kg of CO2 emissions per cubic metre of concrete poured. Based on Banagher's average 60,000 cubic metre output of concrete per year, the savings achieved in these trials mean that the incorporation of CementeneTM could offer almost 4.4 million kg of CO2 savings per year at a cost the Company believes is competitive for this level of emissions reduction. Reported Earnings • Feb 25
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2022 results: UK£0.028 loss per share (improved from UK£0.035 loss in FY 2021). Revenue: UK£7.40m (down 3.6% from FY 2021). Net loss: UK£5.29m (loss narrowed 19% from FY 2021). Revenue missed analyst estimates by 24%. Earnings per share (EPS) exceeded analyst estimates by 56%. Revenue is forecast to stay flat during the next 3 years compared to a 1.7% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Chairman Savory Hill was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • May 13
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2022 results: UK£0.026 loss per share (up from UK£0.045 loss in FY 2021). Revenue: UK£7.63m (up 16% from FY 2021). Net loss: UK£4.94m (loss narrowed 37% from FY 2021). Revenue missed analyst estimates by 100%. Earnings per share (EPS) exceeded analyst estimates by 100%. Over the next year, revenue is expected to shrink by 21% compared to a 18% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings. Price Target Changed • Apr 27
Price target increased to UK£0.35 Up from UK£0.26, the current price target is provided by 1 analyst. New target price is 139% above last closing price of UK£0.15. Stock is down 60% over the past year. The company is forecast to post a net loss per share of UK£0.06 next year compared to a net loss per share of UK£0.045 last year. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Chairman Savory Hill was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Dec 08
First half 2022 earnings: Revenues and EPS in line with analyst expectations First half 2022 results: UK£0.015 loss per share (up from UK£0.024 loss in 1H 2021). Revenue: UK£3.82m (up 41% from 1H 2021). Net loss: UK£2.87m (loss narrowed 31% from 1H 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 39% per year whereas the company’s share price has fallen by 41% per year. Reported Earnings • Aug 06
Full year 2021 earnings released: UK£0.044 loss per share (vs UK£0.027 loss in FY 2020) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2021 results: Revenue: UK£6.57m (down 21% from FY 2020). Net loss: UK£7.78m (loss widened 88% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings. Recent Insider Transactions • Jan 23
CEO & Executive Director recently sold UK£890k worth of stock On the 21st of January, Neill Ricketts sold around 2m shares on-market at roughly UK£0.54 per share. This was the largest sale by an insider in the last 3 months. This was Neill's only on-market trade for the last 12 months. Reported Earnings • Jan 23
First half 2021 earnings released: UK£0.025 loss per share The company reported a poor first half result with increased losses and weaker revenues and control over expenses. First half 2021 results: Revenue: UK£3.12m (down 29% from 1H 2020). Net loss: UK£4.16m (loss widened 121% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Dec 30
New 90-day high: UK£0.41 The company is up 5.0% from its price of UK£0.39 on 01 October 2020. The British market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 13% over the same period. Is New 90 Day High Low • Oct 14
New 90-day low: UK£0.34 The company is down 12% from its price of UK£0.38 on 16 July 2020. The British market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 9.0% over the same period. Reported Earnings • Sep 25
Full year earnings released - UK£0.027 loss per share Over the last 12 months the company has reported total losses of UK£4.15m, with losses widening by 67% from the prior year. Total revenue was UK£8.28m over the last 12 months, down 9.4% from the prior year. Is New 90 Day High Low • Sep 25
New 90-day low: UK£0.35 The company is down 19% from its price of UK£0.43 on 26 June 2020. The British market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 13% over the same period. 